Emerging therapies for diverticular disease of the colon

Journal of Clinical Gastroenterology

Volumn 42, Issue 10, 2008, Pages 1145-1151

  Trivedi, Chirag D ^a,b   Das, Kiron M ^a,b  

^a Department of Medicine   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic; Diverticulosis; Fiber; Mesalamine and probiotic

Indexed keywords

MANNAN; MESALAZINE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE; SULTAMICILLIN; ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; COLON DIVERTICULOSIS; DIET THERAPY; DIETARY FIBER; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; DRUG COMBINATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIETARY FIBER; DIVERTICULITIS, COLONIC; DRUG THERAPY, COMBINATION; HUMANS; MESALAMINE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 58149216827     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318188adc1     Document Type: Review

References (46)

1. Painter NS, Burkitt DP. Diverticular disease of the colon: a deficiency disease of Western civilization. Br Med J. 1971;2: 450-454.
2. Painter NS, Truelove SC, Ardran GM, et al. Segmentation and the localization of intraluminal pressure in the human colon, with special reference to the pathogenesis of colonic diverticula. Gastroenterology. 1968;54(suppl):778-780.
3. Painter NS. The high fibre diet in the treatment of diverticular disease of the colon. Postgrad Med J. 1974;50:629-635.
4. Taylor I, Duthie HL. Bran tablets and diverticular disease. Br Med J. 1976;1:988-990.
5. Brodribb AJ, Humphreys DM. Diverticular disease: three studies. Part II: Treatment with bran. Br Med J. 1976;1:425-428.
6. Brodribb AJ. Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet. 1977;1:664-666.
7. Hodgson WJ. The placebo effect. Is it important in diverticular disease? Am J Gastroenterol. 1977;67:157-162.
8. Hyland JM, Taylor I. Does a high fibre diet prevent the complications of diverticular disease? Br J Surg. 1980;67:77-79.
9. Ornstein MH, Littlewood ER, Baird IM, et al. Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clinical Research ed). 1981;282:1353-1356.
10. Leahy AL, Ellis RM, Quill DS, et al. High fibre diet in symptomatic diverticular disease of the colon. Ann R Coll Surg Engl. 1985;67: 173-174.
11. Smits BJ, Whitehead AM, Prescott P. Lactulose in the treatment of symptomatic diverticular disease: a comparative study with high-fibre diet. Br J Clin Pract. 1990;44:314-318.
12. Finegold SM, Attebery HR, Sutter VL. Effect of diet on human fecal flora: comparison of Japanese and American diets. Am J Clin Nutr. 1974;27:1456-1469.
13. Floch MH, Fuchs HM. Modification of stool content by increased bran intake. Am J Clin Nutr. 1978;31:S185-S189.
14. Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multi-centre open trial. Diverticular Disease Study Group. Ital J Gastroenterol. 1992;24:452-456.
15. Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther. 1995;9:33-39.
16. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003;18:55-62.
17. D'Inca R, Pomerri F, Vettorato MG, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007;25:771-779.
18. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol. 2007;13:264-269.
19. Pistoia MA, Lombardi L, Rossi M, et al. Does rifaximin prevent complications of diverticular disease? A retrospective study. Eur Rev Med Pharmacol Sci. 2004;8:283-287.
20. Ghorai S, Ulbright TM, Rex DK. Endoscopic findings of diverticular inflammation in colonoscopy patients without clinical acute diverticulitis: prevalence and endoscopic spectrum. Am J Gastroenterol. 2003;98:802-806.
21. Imperiali G, Meucci G, Alvisi C, et al. Segmental colitis associated with diverticula: a prospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:1014-1016.
22. Makapugay LM, Dean PJ. Diverticular disease-associated chronic colitis. Am J Surg Pathol. 1996;20:94-102.
23. Peppercorn MA. Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol. 1992;87:609-612.
24. Floch MH, Bina I. The natural history of diverticulitis: fact and theory. J Clin Gastroenterol. 2004;38:S2-S7.
25. Trespi E, Colla C, Panizza P, et al. Ruolo terapeutico e profilattico della mesalazina nella malattia diverticulare sintomatica del crasso. Minerva Gastroenterol Dietol. 1999;45:245-252.
26. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002;34:510-515.
27. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit. 2004;10:PI70-PI73.
28. Di Mario F, Aragona G, Leandro G, et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci. 2005; 50:581-586.
29. Tursi A, Brandimarte G, Giorgetti GM, et al. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2007;52:671-674.
30. Comparato G, Fanigliulo L, Aragona G, et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis (Basel, Switzerland). 2007;25: 252-259.
31. Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J Clin Gastroenterol. 2006;40:S150-S154.
32. MacDermott RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989;96:442-448.
33. Rubinstein A, Das KM, Melamed J, et al. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol. 1978;33:217-224.
34. Stevens C, Lipman M, Fabry S, et al. 5-aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther. 1995; 272:399-406.
35. Craven PA, Pfanstiel J, Saito R, et al. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology. 1987;92: 1998-2008.
36. Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology. 1997;113:1474-1479.
37. Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci. 1985;30:1161-1165.
38. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prosta glandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75: 638-640.
39. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69: 494-497.
40. Harris DW, Swan CH. Increased synthesis of prostaglandins in ulcerative colitis. Lancet. 1977;2:196.
41. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 1981;22: 642-647.
42. Shanahan F, Niederlehner A, Carramanzana N, et al. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology. 1990;20:217-224.
43. Weber CK, Liptay S, Wirth T, et al. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119: 1209-1218.
44. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and syn-biotics - approaching a definition. Am J Clin Nutr. 2001;73: 361S-364S.
45. Giaccari S, Tronci S, Falconieri M, et al. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci. 1993;15: 29-34.
46. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313-315.